Network meta-analysis (NMA) of dextromethorphan-bupropion (AXS-05) efficacy and safety in major depressive disorder

Eur Neuropsychopharmacol. 2024 Sep:86:18-19. doi: 10.1016/j.euroneuro.2024.04.016. Epub 2024 Jun 24.

¹ Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland.
² Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; Department of Public Health, International European University, Kyiv, Ukraine.
³ Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Poland.
⁴ Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. Electronic address: [email protected].
⁵ Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States; Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland; Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland.
⁶ Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.

No abstract available

Keywords: AXS-05; Auvelity; Depression; Dextromethorphan-bupropion; Major depressive disorder.

Publication types